Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

These Mutations are Linked with Worse Survival in CMML

Am J Hematol; 2017 Jan; Patnaik, Barraco, et al

Publish date:: February 12, 2017

DNMT3A mutations were linked with worse overall and leukemia-free survival in people chronic myelomonocytic leukemia (CMML), according to a study involving 261 individuals.

Investigators looked at the impact of such mutations on survival. Among the findings:

DNMT3A mutations were seen in 6% of patients.
8 in every 10 DNMT3A mutations were missense.
31% patients had an abnormal karyotype.
Patients with DNMT3A mutation survived a median of 8 months, vs 27 months in those with wildtype.
DNMT3A mutations were predictive of a shortened leukemia-free survival.

Citation:

Patnaik M, Barraco D, Lasho T, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92(1):56–61. doi:10.1002/ajh.24581.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al